Stock Movers Novo Nordisk Up, Vestas Surges, Babcock Rises
Aug 18, 2025
Novo Nordisk's shares surged after the approval of its weight-loss drug Wegovy for a serious liver condition, outpacing competitors. Vestas experienced a remarkable rise due to favorable IRS tax guidance for clean energy projects, reaching a peak not seen since November. Babcock’s stock gained traction following an outperform rating upgrade from RBC, indicating a bright future in the defense sector. Tune in for insights on these market movements and investment strategies!
AI Snips
Chapters
Transcript
Episode notes
Wegovy Approval Reopens Big Market For Novo
- Novo Nordisk regained momentum after Wegovy won US approval for MASH, opening a large addressable market.
- The approval helps offset prior share losses and competitive pressure from Eli Lilly and GLP-1 copycats.
Tax Guidance Eases US Clean-Energy Risk
- Vestas shares jumped after Treasury and IRS guidance on clean-energy tax credits proved more lenient than feared.
- The guidance clarified construction and in-service timing requirements, reducing project risk for turbine suppliers.
Upgrade Spurs Babcock Outperformance
- RBC upgraded Babcock to outperform, citing strong MoD ties, engineering know-how and management quality.
- The rating and a broader defense sector rally are boosting Babcock above peers in the UK defense support space.